Exactly what the mechanism of oncogenic PRDM9 is remains open to experimental scrutiny, but another feature to consider is the possibility that this serves to assist tumour evolution by garnering instability; it is widely accepted that tumours which have greater propensity to undergo high rates of genomic change and instability are more amenable to evolving therapeutic resistance (Sansregret et al., 2018). Here, PRDM9 is linked to neoplasm.